Kyle E. Harrington

Statistics

Publications

Citations

138

H-Index

Active since

2010

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (France)

Boehringer Ingelheim (Japan)

Boehringer Ingelheim (Germany)

Kyle E. Harrington is an author at Boehringer Ingelheim (United States) specializing in pharmacology, medicinal chemistry, and cardiovascular pharmacodynamics.

Publications per year

2010–2012

Publications

The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P1) and Hypertension (S1P3) in Rat

Ryan M. Fryer, Akalushi Muthukumarana, Paul C. Harrison et al. · PLoS ONE · 2012 · 79 citations · Full text

Medicine, Pharmacology, Physiology +17

SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability

Donghong A. Gao, Zhaoming Xiong, Alexander Heim‐Riether et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Mitigation of Off-Target Adrenergic Binding and Effects on Cardiovascular Function in the Discovery of Novel Ribosomal S6 Kinase 2 Inhibitors

Ryan M. Fryer, Akalushi Muthukumarana, Rong Rhonda Chen et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 18 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Strategic Integration of In Vivo Cardiovascular Models During Lead Optimization

Ryan M. Fryer, Paul C. Harrison, Akalushi Muthukumarana et al. · Journal of Cardiovascular Pharmacology · 2011 · 11 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–4 of 4